Key Takeaways ACB topped Q3 earnings and revenue estimates, with sales rising 7% year over year to about $68 million.ACB's medical cannabis revenue grew roughly 20% over nine months, led by strength in Europe and Australia.ACB plans to exit certain Canadian consumer markets to improve margins despite near-term transition costs.Aurora Cannabis (ACB) recently reported its third-quarter results for fiscal 2026 (year ending March 2026). Both earnings and sales beat our consensus estimates.This Canada-based cann ...

Core Viewpoint - Aurora Cannabis Inc. reported financial results that were in line with expectations, showing revenue growth both year-over-year and quarter-over-quarter [1] Financial Performance - Revenue increased compared to the previous year and the previous quarter [1] - The company reported free cash flow but still incurred an overall net loss [1] Strategic Focus - Aurora Cannabis plans to divest its plant propagation segment to concentrate more on its core business areas [1]

PresentationTheunis Eloff Ladies and gentlemen, welcome to this 25th Annual General Meeting of Astral Foods Limited. Pleasure and welcome you. My name is Theunis Eloff, Chairman of the Board. And in terms of the memorandum of incorporation, I preside as Chairman. The Secretary informs me that the necessary quorum is present, and I declare this meeting properly constituted. I suggest that the notice convening this meeting, which has been circulated and a copy of which is before you be taken as read. Is that ...

Aurora reported consolidated adjusted gross margin of 62%, up 100 basis points year over year, while adjusted gross profit increased 6% to CAD 55.6 million. The medical cannabis segment posted an adjusted gross margin of 69%, which management attributed to the mix shift toward higher-margin international markets as well as sustainable cost reductions and operational efficiencies, including sourcing for Europe from Canada.CFO Simona King said total net revenue was CAD 94.2 million, supported by contributions ...

We are one of Canada's largest global medical cannabis companies. We are Canada's leading exporter of medical cannabis. And finally, we are a market leader in the three biggest nationally legal medical cannabis markets outside of Canada. Notably, about 90% of our annual manufacturing capacity is produced within Aurora's European and TGA GMP-certified facilities and is subject to very stringent international standards. These standards are only increasing, significantly limiting the number of market participa ...

Aurora Cannabis (NasdaqCM:ACB) Q3 2026 Earnings call February 04, 2026 08:00 AM ET Company ParticipantsBrenna Cunnington - Equity Research AssociateDerek Lessard - Director of Equity ResearchKenric Tyghe - Director of Equity Research of Special SituationsKevin Niland - Director of Strategic Finance and Head of Investor RelationsMiguel Martin - Executive Chairman and CEOPablo Zuanic - Founder and Managing PartnerSimona King - CFOConference Call ParticipantsBill Kirk - Managing Director and Senior Research An ...

Aurora Cannabis (NasdaqCM:ACB) Q3 2026 Earnings call February 04, 2026 08:00 AM ET Company ParticipantsBrenna Cunnington - Equity Research AssociateDerek Lessard - Director of Equity ResearchKenric Tyghe - Director of Equity Research of Special SituationsKevin Niland - Director of Strategic Finance and Head of Investor RelationsMiguel Martin - Executive Chairman and CEOPablo Zuanic - Founder and Managing PartnerSimona King - CFOConference Call ParticipantsBill Kirk - Managing Director and Senior Research An ...

Aurora Cannabis (NasdaqCM:ACB) Q3 2026 Earnings call February 04, 2026 08:00 AM ET Speaker3Welcome to the Aurora Cannabis Inc. third quarter 2026 results conference call. All participants will be in a listen-only mode, and a question-and-answer session will follow the formal presentation. This conference call is being recorded today, Wednesday, February 4, 2026. I would now like to turn the conference over to your host, Kevin Nyland, Director of Strategic Finance and Investor Relations. Please go ahead, sir ...

INVESTOR PRESENTATION FY26 Q3 February 2026 Disclaimer CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information contained in this presentation constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "in ...

A prospectus supplement (the "Prospectus Supplement") to the Company's short form base shelf prospectus dated February 14, 2025 (the "Base Shelf Prospectus") has been filed with the securities commissions or securities regulatory authorities in each of the provinces of Canada, except Quebec, and with the U.S. Securities and Exchange Commission (the "SEC") as part of the Company's registration statement on Form F-10 (the "Registration Statement") under the U.S./Canada Multijurisdictional Disclosure System. T ...